Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

Bahl, A.; Oudard, S.; Tombal, B.; Ozguroglu, Mustafa; Hansen, S.; Kocak, I.; Gravis, G.; Devin, J.; Shen, L.; de Bono, J.; Sartor, A.

doi:10.1093/annonc/mdt194

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

Atıf İçin Kopyala

Bahl A., Oudard S., Tombal B., Ozguroglu M., Hansen S., Kocak I., ...Daha Fazla

ANNALS OF ONCOLOGY, cilt.24, sa.9, ss.2402-2408, 2013 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 24 Sayı: 9
Basım Tarihi: 2013
Doi Numarası: 10.1093/annonc/mdt194
Dergi Adı: ANNALS OF ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.2402-2408
İstanbul Üniversitesi Adresli: Evet

Özet

Cabazitaxel significantly improves overall survival (OS) versus mitoxantrone in patients with metastatic castration-resistant prostate cancer after docetaxel failure. We examined patient survival at 2 years and tumour-related pain with cabazitaxel versus mitoxantrone.